You are using an outdated browser. Please upgrade your browser to improve your experience and security.

What is AML?

Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. In AML, the bone marrow makes abnormal myeloblasts (a type of white blood cell). These abnormal cells are called leukemia cells, or blasts.

Acute leukemia is monitored by measuring the amount of blasts. Because it is a rapidly progressing cancer, the cells divide quickly and the disease may spread fast. As the percentage of blasts increases, the bone marrow is less able to create normal white and red blood cells and platelets.

View more important AML facts.
Bone Marrow From Healthy Patient and AML Patient part 1 of 5

Bone marrow from
healthy patient

Bone Marrow From Healthy Patient and AML Patient part 2 of 5

Bone marrow from
patient with AML

Bone Marrow From Healthy Patient and AML Patient part 3 of 5

Red blood cell

Bone Marrow From Healthy Patient and AML Patient part 4 of 5

White blood cell

Bone Marrow From Healthy Patient and AML Patient part 5 of 5

Leukemia cell

The video below will teach you more about AML and how it develops in the body.

WHAT IS VYXEOS?

VYXEOS is a prescription intravenous (IV) chemotherapy used for the treatment of adults with certain types of newly-diagnosed acute myeloid leukemia (AML). These types include patients whose AML is related to previously received chemotherapy or radiation therapy (also called therapy-related AML, t-AML) and AML in patients who previously had certain types of blood disorders, have a specific genetic mutation, or have certain abnormal blood cells (also called AML with myelodysplasia-related changes, AML-MRC).

IMPORTANT SAFETY INFORMATION

Important Safety Information

VYXEOS has different dosage recommendations from other medications that contain daunorubicin and/or cytarabine. Do not substitute VYXEOS for other daunorubicin and/or cytarabine-containing products.